ERYTECH Pharma (ERYP) Stock Price, News & Analysis

Company Overview

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Key Stats

• Today's Range: $3.10 to $3.10
• 50-Day Range: $4.19 to $5.08
• 52-Week Range: $0.30 to $1.47
• Volume: N/A
• Average Volume: 93,510 shs
• Market Capitalization: $105.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ERYP Stock Analysis - Frequently Asked Questions

When did ERYTECH Pharma IPO?

ERYTECH Pharma (ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ERYTECH Pharma investors own include Ardelyx (ARDX), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN), Pfizer (PFE), Sesen Bio (SESN), Nymox Pharmaceutical (NYMX) and ObsEva (OBSV).

Company Calendar

• Today: 5/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ERYP
• CIK: 1624422
• Web: www.erytech.com
• Phone: (347) 874-4438
• Fax: 33-4-78-75-56-29
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 3.65
• Quick Ratio: 3.65

Sales & Book Value

• Annual Sales: $32.66 million
• Price / Sales: 3.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.80 per share
• Price / Book: 3.88

Miscellaneous

• Outstanding Shares: 34,120,000
• Free Float: 33,458,000
• Market Cap: $105.77 million
• Optionable: Not Optionable
• Beta: 2.69